MX2021009626A - Metodos y composiciones para el tratamiento de gastritis de celulas cebadas, esofagitis de celulas cebadas, enteritis de celulas cebadas, duodenitis de celulas cebadas y/o gastroenteritis de celulas cebadas. - Google Patents
Metodos y composiciones para el tratamiento de gastritis de celulas cebadas, esofagitis de celulas cebadas, enteritis de celulas cebadas, duodenitis de celulas cebadas y/o gastroenteritis de celulas cebadas.Info
- Publication number
- MX2021009626A MX2021009626A MX2021009626A MX2021009626A MX2021009626A MX 2021009626 A MX2021009626 A MX 2021009626A MX 2021009626 A MX2021009626 A MX 2021009626A MX 2021009626 A MX2021009626 A MX 2021009626A MX 2021009626 A MX2021009626 A MX 2021009626A
- Authority
- MX
- Mexico
- Prior art keywords
- mast cell
- duodenitis
- gastroenteritis
- esophagitis
- enteritis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/062—Gastritis or peptic ulcer disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806604P | 2019-02-15 | 2019-02-15 | |
| US201962925704P | 2019-10-24 | 2019-10-24 | |
| PCT/US2020/018405 WO2020168271A1 (en) | 2019-02-15 | 2020-02-14 | Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009626A true MX2021009626A (es) | 2021-09-08 |
Family
ID=72044142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009626A MX2021009626A (es) | 2019-02-15 | 2020-02-14 | Metodos y composiciones para el tratamiento de gastritis de celulas cebadas, esofagitis de celulas cebadas, enteritis de celulas cebadas, duodenitis de celulas cebadas y/o gastroenteritis de celulas cebadas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220135673A1 (enExample) |
| EP (1) | EP3923986A4 (enExample) |
| JP (1) | JP2022520105A (enExample) |
| KR (1) | KR20210126084A (enExample) |
| CN (1) | CN113747918A (enExample) |
| AU (1) | AU2020223365A1 (enExample) |
| BR (1) | BR112021015009A2 (enExample) |
| CA (1) | CA3130072A1 (enExample) |
| IL (1) | IL285430A (enExample) |
| MX (1) | MX2021009626A (enExample) |
| SG (1) | SG11202108833QA (enExample) |
| WO (1) | WO2020168271A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019022912A2 (pt) | 2017-05-05 | 2020-05-26 | Allakos Inc. | Métodos e composições para tratar doenças oculares alérgicas |
| MX2019013136A (es) * | 2017-05-05 | 2020-07-14 | Allakos Inc | Metodos y composiciones para tratar trastornos gastrointestinales inflamatorios. |
| WO2021081411A1 (en) * | 2019-10-24 | 2021-04-29 | Allakos Inc. | Methods and compositions for treating irritable bowel syndrome and functional dyspepsia |
| AU2021365008A1 (en) * | 2020-10-22 | 2023-06-08 | Allakos Inc. | Anti-siglec-8 antibody formulations |
| WO2022187834A1 (en) * | 2021-03-03 | 2022-09-09 | Allakos Inc. | Anti-siglec-8 antibody formulations |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| KR20250007535A (ko) * | 2022-04-22 | 2025-01-14 | 인히브릭스 바이오사이언스, 인크. | Siglec-8 결합 단백질 및 그 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2465873A1 (en) * | 2010-12-16 | 2012-06-20 | Deutsches Rheuma-Forschungszentrum Berlin | Eosinophils as a therapeutic target |
| KR20210125114A (ko) * | 2013-12-09 | 2021-10-15 | 알라코스 인크. | 항-Siglec-8 항체 및 그의 사용 방법 |
| MX2019013136A (es) * | 2017-05-05 | 2020-07-14 | Allakos Inc | Metodos y composiciones para tratar trastornos gastrointestinales inflamatorios. |
-
2020
- 2020-02-14 BR BR112021015009-9A patent/BR112021015009A2/pt not_active IP Right Cessation
- 2020-02-14 KR KR1020217029121A patent/KR20210126084A/ko not_active Ceased
- 2020-02-14 CN CN202080028635.6A patent/CN113747918A/zh active Pending
- 2020-02-14 CA CA3130072A patent/CA3130072A1/en active Pending
- 2020-02-14 US US17/430,256 patent/US20220135673A1/en not_active Abandoned
- 2020-02-14 SG SG11202108833QA patent/SG11202108833QA/en unknown
- 2020-02-14 MX MX2021009626A patent/MX2021009626A/es unknown
- 2020-02-14 EP EP20756504.5A patent/EP3923986A4/en not_active Withdrawn
- 2020-02-14 AU AU2020223365A patent/AU2020223365A1/en active Pending
- 2020-02-14 JP JP2021547415A patent/JP2022520105A/ja active Pending
- 2020-02-14 WO PCT/US2020/018405 patent/WO2020168271A1/en not_active Ceased
-
2021
- 2021-08-08 IL IL285430A patent/IL285430A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021015009A2 (pt) | 2021-10-05 |
| CA3130072A1 (en) | 2020-08-20 |
| US20220135673A1 (en) | 2022-05-05 |
| WO2020168271A1 (en) | 2020-08-20 |
| KR20210126084A (ko) | 2021-10-19 |
| EP3923986A4 (en) | 2022-10-12 |
| SG11202108833QA (en) | 2021-09-29 |
| EP3923986A1 (en) | 2021-12-22 |
| AU2020223365A1 (en) | 2021-08-26 |
| JP2022520105A (ja) | 2022-03-28 |
| CN113747918A (zh) | 2021-12-03 |
| IL285430A (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| PH12020551932A1 (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
| ZA201907372B (en) | Methods and compositions for treating inflammatory gastrointestinal disorders | |
| PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| NZ724229A (en) | Anti-egfrviii antibodies and uses thereof | |
| PH12022550141A1 (en) | Immunomodulatory antibodies and methods of use thereof | |
| EP4442278A3 (en) | Humanized antibodies against c-kit | |
| MX2012011543A (es) | Tratamiento de sarcoidosis empleando celulas madre placentarias. | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| BR112017020952A2 (pt) | método de tratamento de câncer, composição e uso da composição | |
| EP4389142A3 (en) | Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| MX2019004834A (es) | Anticuerpos de pd-1 y usos de estos. | |
| TN2016000553A1 (en) | Methods and compositions for treating ulcers | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| SG10201803845SA (en) | Pyrazole derivatives as modulators of calcium release -activated calcium channel | |
| JOP20200022A1 (ar) | مركبات حلقية لولبية وطرق تصنيعها واستخدامها | |
| EP4316596A3 (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer | |
| MX2020010722A (es) | Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos. | |
| WO2019090347A8 (en) | Adenosine pathway inhibitors for cancer treatment | |
| PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
| IL285430A (en) | Methods and preparations for the treatment of mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis | |
| ZA201907371B (en) | Methods and compositions for treating allergic ocular diseases | |
| MX2020014091A (es) | Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un agente de platino y un inhibidor de la topoisomerasa ii. | |
| MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. |